Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 377Myelodysplastic Syndromes 159Leukemia, Myelomonocytic, Chronic 76Leukemia 65Recurrence 32Myeloproliferative Disorders 23Hematologic Neoplasms 20Neoplasms 19Multiple Myeloma 17Carcinoma, Non-Small-Cell Lung 17Lymphoma, Non-Hodgkin 16Lymphoma 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Lymphoma, Large B-Cell, Diffuse 14Anemia, Refractory, with Excess of Blasts 14Lymphoma, T-Cell, Peripheral 13Primary Myelofibrosis 12Neoplasm, Residual 12Leukemia, Monocytic, Acute 11Leukemia, Lymphocytic, Chronic, B-Cell 11Leukemia, Biphenotypic, Acute 11Leukemia, Myelomonocytic, Acute 10Hodgkin Disease 10Myelodysplastic-Myeloproliferative Diseases 9Leukemia, Erythroblastic, Acute 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myeloid 8Leukemia, Megakaryoblastic, Acute 8Congenital Abnormalities 8Breast Neoplasms 8

Interventions

luspatercept 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Higher-risk Myelodysplastic Syndrome × Azacitidine × Clear all
NCT06927232 2025-04-15

AZA+Lus VS AZA Monotherapy in HR-MDS

Peking Union Medical College Hospital

Phase 3 Not yet recruiting
86 enrolled
Myeloid

Higher-risk Myelodysplastic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡